Reaction
Cushing'S Syndrome reporting signals
As of the last recalculation, Cushing'S Syndrome appears in 696 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is RITONAVIR 100 MG (PRR 173.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ritonavir 100 Mg | 77 | 173.2 | 174.1 |
| Clobetasol Propionate Ointment Usp, 0.05% | 50 | 156.3 | 157.1 |
| Clobetasol Propionate | 50 | 155.7 | 156.5 |
| Ritonavir | 123 | 152.7 | 153.3 |
| Atazanavir | 61 | 139.0 | 139.6 |
| Lopinavir And Ritonavir | 56 | 134.3 | 134.8 |
| Abacavir Sulfate | 17 | 53.5 | 53.6 |
| Tenofovir Disoproxil Fumarate Tablets | 15 | 53.1 | 53.2 |
| Fluticasone Propionate Nasal | 49 | 51.9 | 52.0 |
| Lamivudine | 47 | 48.7 | 48.8 |
| Nevirapine | 14 | 47.3 | 47.4 |
| Lamivudine Oral | 37 | 46.1 | 46.2 |
| Zidovudine | 17 | 38.9 | 39.0 |
| Darunavir | 17 | 34.4 | 34.5 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 24 | 31.7 | 31.7 |
| Itraconazole | 12 | 31.2 | 31.3 |
| Triamcinolone Acetonide | 25 | 25.1 | 25.1 |
| Salmeterol Xinafoate | 7 | 24.5 | 24.5 |
| Dexamethasone Sodium Phosphate | 8 | 23.8 | 23.8 |
| Fondaparinux Sodium | 6 | 22.4 | 22.4 |
| Efavirenz | 8 | 21.7 | 21.7 |
| Tenofovir Disoproxil Fumarate | 22 | 20.5 | 20.5 |
| Raltegravir | 9 | 16.5 | 16.5 |
| Emtricitabine And Tenofovir Disoproxil Fumarate | 22 | 14.9 | 14.9 |